由Rohit Batta博士领导的Alethio治疗疗法正在研制两种慢性血癌抗体药物共生疗法,其中一种在临床前测试中表现出希望。 Alethio Therapeutics, led by Dr. Rohit Batta, is developing two antibody-drug conjugate therapies for chronic blood cancers, with one showing promise in preclinical tests.

在Rohit Batta博士担任首席执行官和Mike Grey担任董事会主席的情况下,Alethio治疗疗法已经启动,重点是开发两种抗体药物共生疗法,以治疗一种慢性血癌,即宫颈增生肿瘤(MPNs)。 Alethio Therapeutics has launched with Dr. Rohit Batta as CEO and Mike Grey as Board Chair, focusing on developing two antibody-drug conjugate therapies for myeloproliferative neoplasms (MPNs), a group of chronic blood cancers. AT-01是针对纤维质骨髓中的变异干细胞的一流治疗,其临床预科结果大有希望,并正在准备在2026年初进行IND/CTA助学研究。 AT-01, a first-in-class therapy targeting mutant stem cells in fibrotic bone marrow, showed promising preclinical results and is preparing for IND/CTA-enabling studies in early 2026. 第二个方案,AT-02,针对大约30%的MPN病人中的变种CALR,正在进行临床前期评估。 A second program, AT-02, targets mutant CALR in about 30% of MPN patients and is in preclinical evaluation. 该公司利用一个专门的发现平台和进入世界上最大的MPN病人细胞储存库,以确定旨在改变疾病、而不仅仅是管理症状的精确治疗方法。 The company uses a specialized discovery platform and access to one of the world’s largest MPN patient cell repositories to identify precise treatments aimed at modifying the disease rather than just managing symptoms.